Hønge Bo L, Andersen Morten N, Jespersen Sanne, Medina Candida, Correira Faustino G, Jakobsen Martin R, Laursen Alex, Erikstrup Christian, Møller Holger J, Wejse Christian
*Department of Clinical Immunology, Aarhus University Hospital, Denmark;†Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau;Departments of ‡Infectious Diseases;§Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark;‖Department of Biomedicine, Aarhus University, Denmark;¶National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau; and#GloHAU, Center for Global Health, School of Public Health, Aarhus University, Aarhus, Denmark.
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):254-8. doi: 10.1097/QAI.0000000000000939.
The course of disease among HIV-2, HIV-1, and HIV-1/2 dually infected patients is different. We investigated the macrophage activation marker soluble CD163 (sCD163) dynamics in 212 HIV-1, HIV-2, and HIV-1/2 dually infected patients. There were no differences in sCD163 levels at baseline or during follow-up without antiretroviral therapy (ART). At follow-up on ART, median sCD163 levels were decreased for HIV-1-infected patients (P < 0.001), but not among HIV-2 (P = 0.093) or HIV-1/2 dually infected patients (P = 0.145). The larger decrease in sCD163 levels among HIV-1-infected patients during ART may indicate an HIV type-dependent differential effect of ART on macrophage activation during HIV infection.
HIV-2、HIV-1以及HIV-1/2双重感染患者的病程有所不同。我们调查了212例HIV-1、HIV-2以及HIV-1/2双重感染患者体内巨噬细胞活化标志物可溶性CD163(sCD163)的动态变化。在未接受抗逆转录病毒治疗(ART)时,基线或随访期间的sCD163水平并无差异。在接受ART随访时,HIV-1感染患者的sCD163水平中位数有所下降(P < 0.001),但HIV-2感染患者(P = 0.093)以及HIV-1/2双重感染患者(P = 0.145)的sCD163水平并未下降。HIV-1感染患者在ART期间sCD163水平下降幅度更大,这可能表明在HIV感染期间,ART对巨噬细胞活化的影响存在HIV类型依赖性差异。